Ocugen soaring ahead of key WHO meeting tomorrow on partner’s COVID-19 shot

Oct. 25, 2021 5:14 PM ETOcugen, Inc. (OCGN)By: Dulan Lokuwithana, SA News Editor24 Comments

India"s Covaxin Vaccine Administered In Harare

Tafadzwa Ufumeli/Getty Images News

  • Ocugen (NASDAQ:OCGN) shares are rising in the post-market ahead of a meeting by an advisory panel of the World Health Organization (WHO) on Tuesday to discuss whether to grant an emergency use listing for its partner’s COVID-19 vaccine named Covaxin.
  • Currently, the stock has added ~13.7% in the post-market, with ~5.3M shares changing hands compared to the 65-day average of ~16.0M.
  • WHO will make a decision on the vaccine developed by Bharat Biotech based on the recommendations of the Technical Advisory Group tomorrow.
  • Social media is abuzz with speculation that the WHO has already greenlighted the vaccine as the global body has posted on its website several documents related to the vaccine ahead of the meeting tomorrow.
  • Ocugen (OCGN) partnered with Bharat Biotech to co-develop Covaxin for the U.S. market, and in late-stage trials, it has shown about 78% efficacy against COVID-19.

Recommended For You

Comments (24)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.